Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | AMV-564 |
Trade Name | |
Synonyms | AMV564|AMV 564|T652 |
Drug Descriptions |
AMV-564 is a tandem diabody that targets both CD33 and CD3, which may result in increased T-cell activation and death of CD33-expressing tumor cells (PMID: 27189165, PMID: 28157217). |
DrugClasses | CD3 Antibody 99 CD33 Antibody 13 |
CAS Registry Number | 2243775-32-6 |
NCIT ID | C135632 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AMV-564 | AMV-564 | 0 | 3 |
AMV-564 + Pembrolizumab | AMV-564 Pembrolizumab | 0 | 0 |